Platform Technologies - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Platform Technologies
The standardization of upstream and downstream bioprocessing is growing, but several kinks need to be ironed out.

Pharmaceutical Technology
Volume 36, Issue 3, pp. 46-50

PharmTech: Looking ahead, how can platform technologies for analytical methods be improved? Can methods for detecting contaminating proteins, host-cell proteins, and protein level be standardized? What new technologies or methods could help?

Atkinson (Cook): Analytical methods, by definition, should theoretically be amenable to platform standardization. As mentioned, the primary purpose is to detect process- and product-related impurities. The challenge for process-related impurities is that each upstream platform produces different impurities, such as type and amount of HCPs. Unfortunately 'generic' commercial kits are often poor substitutes for process-specific detection methods, but do serve a purpose when used consistently in a platform.

For product-related impurities, the challenge is similar to that for downstream processing, and depends on specific molecular variants. In addition, the analytical technologies employed are not yet standardized. Charge variants, for instance, can be detected by at least four different methods, none of which effectively discriminate amongst several types of variants (e.g., sialic acid content, deamidation).

If the platform methods are developed in parallel with the process, and used and controlled consistently, then they can be useful within the portfolio they are employed. Process-related impurities are better understood and controlled, and minor modifications can be made to address product-related impurities. However, the relative utility of the platform is lessened when applied more broadly across product portfolios.

Ideal analytical methods would both separate and identify unique molecular species. A high-throughput, quality-control friendly functional equivalent to an LC–MS method would be desirable.

Moesta (Bristol-Myers): Most straightforward analytical methods such as A280, capillary electrophoresis, polyacrylamide gel electrophoresis, isoelectric focusing, and size-exclusion high-performance liquid chromatography, are flexible and lend themselves for upstream and downstream analyses. More complex methodologies, particularly for unique post-translational modifications and potency, are not as easily standardized, particularly those requiring high-end analytical endpoints such as mass spectrometry (MS), nuclear magnetic resonance (NMR), surface plasmon resonance for binding kinetics, and cell-based bioassays.

Once projects progress to the clinical-trial stage, it is advisable to take a closer look at standardized methods and optimize them for the molecule at hand.

The first requirement for being able to facilitate the use of an analytical platform is that the master cell line, expression vector, and upstream and downstream process steps are standardized as much as possible. The better characterized and standardized the process, a combination of anti-sera reactive against known impurities and HCPs can be created from premade anticontaminant libraries to provide sufficient coverage and sensitivity. Protein-A detection methods are relatively easy to platform while HCP methods tend to be the most challenging.

Newer surface-plasmon resonance instrumentation is providing for significant improvement in the throughput and robustness required for ligand binding and binding kinetics assays. With particular molecule classes (e.g., mAbs), standardization of common reagents and capture approaches can improve and simplify the method development of specific binding activity method platforms.

For cell-based bioassays (potency), the use of common cell-based systems, either off the shelf or specifically designed, and activity read-outs for classes of activities (e.g. cytokine production, cell migration, etc.), can significantly reduce the amount of de novo method development. Also, the standardization of read-outs such as chemiluminescence or enzyme-generated colorimetric measurements in a microtiter plate format can further improve throughput.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here